Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)‘s stock had its “buy” rating reiterated by stock analysts at Noble Financial in a research note issued to investors on Friday. They currently have a $16.00 price objective on the biopharmaceutical company’s stock. Noble Financial’s price objective would suggest a potential upside of 123.78% from the company’s previous close.

Several other brokerages also recently commented on CRBP. BidaskClub raised shares of Corbus Pharmaceuticals Holdings from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. ValuEngine downgraded shares of Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a report on Wednesday, September 13th. Finally, Cantor Fitzgerald set a $24.00 price target on shares of Corbus Pharmaceuticals Holdings and gave the company a “buy” rating in a report on Monday, July 17th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $19.75.

Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) remained flat at $7.15 on Friday. 380,750 shares of the company were exchanged. Corbus Pharmaceuticals Holdings has a 12 month low of $4.65 and a 12 month high of $10.78. The company has a 50 day moving average price of $6.51 and a 200-day moving average price of $6.90. The stock’s market capitalization is $348.21 million.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. Corbus Pharmaceuticals Holdings had a negative net margin of 1,001.77% and a negative return on equity of 107.10%. The firm had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.50 million. Equities research analysts expect that Corbus Pharmaceuticals Holdings will post ($0.66) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2017/09/29/corbus-pharmaceuticals-holdings-inc-crbp-now-covered-by-noble-financial.html.

A number of large investors have recently made changes to their positions in CRBP. Artal Group S.A. purchased a new stake in shares of Corbus Pharmaceuticals Holdings during the 2nd quarter valued at $1,575,000. Alps Advisors Inc. purchased a new stake in shares of Corbus Pharmaceuticals Holdings during the 2nd quarter valued at $286,000. Vanguard Group Inc. raised its position in shares of Corbus Pharmaceuticals Holdings by 6.0% during the 1st quarter. Vanguard Group Inc. now owns 1,255,429 shares of the biopharmaceutical company’s stock valued at $10,357,000 after buying an additional 71,419 shares in the last quarter. Highbridge Capital Management LLC raised its position in shares of Corbus Pharmaceuticals Holdings by 38.4% during the 1st quarter. Highbridge Capital Management LLC now owns 73,696 shares of the biopharmaceutical company’s stock valued at $608,000 after buying an additional 20,437 shares in the last quarter. Finally, BlueCrest Capital Management Ltd purchased a new stake in shares of Corbus Pharmaceuticals Holdings during the 1st quarter valued at $246,000. 31.78% of the stock is owned by hedge funds and other institutional investors.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.